Clinical Trials List
Protocol NumberJ3R-MC-YDAF
Not yet recruiting
2026-02-01 - 2029-02-24
Phase III
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 黃天祈 Division of Cardiovascular Diseases
- Chun-Yuan Chu Division of Cardiovascular Diseases
- 李純瑩 Division of Family Medicine
- Mei Yueh Lee Division of Endocrinology
- Ye-Hsu Lu Division of Cardiovascular Diseases
Co-Principal Investigator
- 蔡嘉仁 Division of Endocrinology
- 沈峰志 Division of Endocrinology
- 陳永年 Division of Endocrinology
- 黃偉城 Division of Family Medicine
- 郭銘俊 Division of Endocrinology
- 徐莞嘉 Division of Endocrinology
- 陳玟潔 Division of Endocrinology
- 周依文 Division of Endocrinology
- 林麗珊 Division of Endocrinology
- 藍婕 Division of Family Medicine
Co-Principal Investigator
- 林承緯 Division of Endocrinology
- Chun-Hsiu Liu Division of Ophthalmology
- 林怡瑄 Division of Endocrinology
- 陳怡文 Division of Endocrinology
- Chih-Yiu Tsai Division of Endocrinology
Co-Principal Investigator
- 蘇冠伃 Division of Endocrinology
- 柯富翔 Division of Endocrinology
- Chin-Sung Kuo Division of Endocrinology
- 吳崇暉 Division of Endocrinology
Co-Principal Investigator
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40-60 participants
-
Global
1035 participants
